Cellzome Hits Two Milestones in GSK Kinase Research Pact | GenomeWeb

This story originally ran on Sept. 14.

Proteomics firm Cellzome said this week it has hit a clinical candidate milestone and a lead declaration milestone as part of its agreement with GlaxoSmithKline for the use of its Kinobeads chemoproteomic kinase research platform.

Under the agreement, which the two companies signed in September 2008, achievement of these milestones triggers undisclosed payments from GSK.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.